The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C10 | Lipid modifying agents | |
3
|
C10A | Lipid modifying agents, plain | |
4
|
C10AX | Other lipid modifying agents | |
5
|
C10AX19 |
| Active Ingredient |
|---|
|
Lerodalcibep is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. |
| Document | Type | Information Source | |
|---|---|---|---|
| LEROCHOL Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |